MILLENIA HOPE INC.
(Exact name of Small Business Issuer as Specified in its Charter)
DELAWARE 98-0213828
(state or other Jurisdiction of (I.R.S Employer
Incorporation or Organization) Identification No.)
4055 Ste Catherine st. suite 142, Montreal, Quebec H3Z 3J8
(Address of Principal Executive Offices)
(514) 846-5757
Issuer's Telephone Number Including Area Code)
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date : At August 31, 2000 Issuer had
outstanding 20528590 shares of Common Stock.
INDEX
PART I: FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
Consolidated Balance Sheets (Unaudited) at August 31, 2000. Consolidated
statements of Operations (Unaudited) for the three months and the nine months
ended August 31, 2000 and August 31, 1999, and from inception (December 24,
1997) to August 31, 2000. Statements of cash flows (Unaudited) for the nine
months ended August 31, 2000 and August 31, 1999, and from inception (December
24, 1997) to August 31, 2000. Notes to the Financial Statements (Unaudited)
Item 2. Plan of Operations
PART II. Other Information
Item 2. Sale of Unregistered Securities
Item 6. Exhibits and Reports on Form
SIGNATURES
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
CONSOLIDATED BALANCE SHEET
August 31, 2000
(UNAUDITED)
Assets
2000
------------
Current Assets
Cash and cash equivalents $ 1,001,045
Receivables net 33,600
Other current assets 76,400
Total current assets 1,111,045
Property and equipment, net 91,462
Excess of Cost over book value of subsidiary 1,548,987
Other assets 51,185
Total assets 2,802,679
Liabilities and Shareholder's Equity
Current Liabilities
Accounts payable 4,500
Other current liabilities 21,220
Total curent liabilities 25,720
Minority Interest 1,779,743
Shareholder's Equity
Common Stock, $,0001 par value; authorized 2,052
70,000,000 shares; issued and outstanding
20,528,590 in 2000 and 11,211,220 in 1999
Paid in Capital 12,496,074
Cost of Treasury Shares (7,499,900)
Deficit accumulated during the development stage (4,001,010)
Total Shareholder's Equity 997,216
Total liabilities and shareholder's equity $ 2,802,679
============
Read the accompanying summary of significant policies and notes to financial
statements, both of which are an integral part of this financial statement.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF OPERATIONS
FOR THE THREE MONTHS AND NINE MONTHS ENDED AUGUST 31, 2000 AND AUGUST 31, 1999
AND THE PERIOD FROM THE INCEPTION
(DECEMBER 24, 1997) TO AUGUST 31, 2000
(UNAUDITED)
<TABLE>
<CAPTION>
Inception
3 months ended 9 months ended (Dec. 24, 1997)
AUG. 31, 2000 AUG. 31, 1999 AUG. 31, 2000 AUG. 31, 1999 AUG. 31, 2000
------------- ------------- ------------- ------------- ------------
<S> <C> <C> <C> <C> <C>
Revenue:
$ 62,573 $ 7,500 $ 77,573 $ 20,000 $ 105,073
Operating expenses:
Patent Rights 91,933 258,527 91,933 258,527
1,097,760
Marketing -- -- -- 1,514,215 1,514,215
Other Development Costs -- -- -- -- 218,515
Rent 28,887 15,313 67,087 45,938 204,737
Travel 50,091 -- 90,321 -- 212,321
Consulting 87,554 -- 87,554 -- 87,554
Selling, general and
administrative expenses 163,520 14,521 231,279 43,242 643,282
------------ ------------ ------------ ------------ ------------
Total operating expenses 421,985 288,361 568,174 1,861,922 3,978,384
Loss before other
income (expense) (359,412) (280,861) (490,601) (1,841,922) (3,873,311)
Other income (expense):
Interest expense -- (15,429) (27,770) (44,263) (149,639)
------------ ------------ ------------ ------------ ------------
Total other income (expense) -- (15,429) (27,770) (44,263) (149,639)
Net (Loss) before minority
Interest (359,412) (296,290) (518,371) (1,886,185) (4,022,950)
Minority interest in net (loss)
Of subsidiary (21,939) -- (21,939) -- (21,939)
------------ ------------ ============ ============ ============
Net loss (337,473) (296,290) (496,432) (1,886,185) (4,001,010)
Basic weighted average common
shares outstanding 20,455,778 10,508,244 14,838,538 10,363,493 12,179,153
------------ ------------ ============ ============ ============
Basic Loss per common share $ (0.0165) $ (0.0282) $ (0.0335) $ (0.1820) $ (0.3285)
------------ ------------ ============ ============ ============
</TABLE>
Read the accompanying summary of significant policies and notes to financial
statements, both of which are an integral part of this financial statement.
<PAGE>
MILLENIA HOPE INC.
(A COMPANY IN THE DEVELOPMENT STAGE)
STATEMENT OF CASH FLOWS
FOR THE 9 MONTHS ENDED AUGUST 31, 2000 AND AUGUST 31, 1999
AND THE PERIOD FROM THE INCEPTION
(DECEMBER 24, 1997) TO AUGUST 31, 2000
(UNAUDITED)
<TABLE>
<CAPTION>
Inception
9 Months Ended (Dec. 24, 1997)
AUG 31, 2000 AUG 31, 1999 AUG 31, 2000
------------ ------------ ------------
<S> <C> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income (Loss) $ (496,432) $ (1,886,185) (4,001,010)
Adjustments to reconcile net income (loss) to net cash
used in operating activities:
Depreciation and amortization 13,011 11,083 42,775
Issuance of stock for marketing services -- 1,514,215 1,514,215
Issuance of note for other development costs -- -- 192,831
Operating expenses settled with issuance of note 93,602 -- 93,602
Interest expense settled with issuance of note 27,770 -- 27,770
Changes in Operating assets and liabilities:,
Receivables and other assets (161,185) -- (161,185)
Accounts payable and notes payable (150,930) 85,313 (25,720)
------------- ------------- -------------
Net cash provided by/(used in) operating activities (674,164) (275,574) (2,265,282)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment (43,236) -- (119,236)
Change in cost over book value of subsidiary 95,442 -- 95,442
Change in minority interest (24,494) -- (24,494)
------------- ------------- -------------
Net cash provided by/(used in) investing activities (27,712) -- (48,288)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from:
Notes payable, principally related parties (net of discount) -- 258,527 1,223,853
Issuance of stock 478,564 -- 925,764
Contribution to paid in capital 1,165,000 -- 1,165,000
------------- ------------- -------------
Net cash provided by/(used in) financing activities 1,643,564 288,527 3,314,617
------------- ------------- -------------
Net increase (decrease) in cash and cash equivalents 997,112 (17,047) 1,001,045
Cash and cash equivalents, beginning of period 3,933 21,000 --
------------- ------------- -------------
Cash and cash equivalents, end of period 1,001,045 3,953 1,001,045
============= ============= =============
</TABLE>
On April 30, 2000, the company's subsidiary issued 600,000 shares for Equipment
valued at $15,000. On February 28, 2000, the company, by issuing 4,644,156
warrants, settled notes payable to related parties in the amount of $1,393,247.
Read the accompanying summary of significant accounting policies and notes to
financial statement, both of which are an integral part of this financial
statement.
<PAGE>
NOTE 1 - BASIS OF PRESENTATION
The accompanying unaudited consolidated financial statements of Millenia
Hope Inc. have been prepared in accordance with generally accepted accounting
principles for interim financial information and with the instructions to Form
10-QSB and Article 10 of Regulation S-X. The financial statements reflect all
adjustments consisting of normal recurring adjustments, which, in the opinion of
management, are necessary for a fair presentation of the results for the periods
shown. Accordingly, they do not include all of the information and footnotes
required by generally accepted accounting principles for complete financial
statements.
These financial statements should be read in conjunction with the audited
financial statements and footnotes thereto included in Millenia Hope Inc.'s
Registration Statement on Form 10SB (Registration No. 000-29385) as filed with
the Securities and Exchange Commission.
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and that effect the reported amounts of revenues and expenses during
the reporting period. Actual results could differ from those estimates.
NOTE 2 - REVENUE RECOGNITION
The company currently recognizes revenue in the form of licensing fees,
which are recorded over the life of the licensing agreement using the
straight-line method.
The company also recognizes revenue from its subsidiary, providing
technology related services, such as data storage and consulting. Revenue is
recognized when the service is performed.
In December 1999, the Securities and Exchange Commission ("SEC") issued
Staff Accounting Bulletin No. 101 ("SAB 101"), "Revenue Recognition," which
provides guidance on the recognition, presentation and disclosure of revenue in
financial statements filed with the SEC. SAB 101 outlines the basic criteria
that must be met to recognize revenue and provide guidance for disclosures
related to revenue recognition policies. Management believes that Millenia Hope
Inc.'s revenue recognition practices are in conformity with the guidelines of
SAB 101.
NOTE 3 - NET LOSS PER SHARE
Basic earnings (loss) per share is computed using the weighted-average
number of common shares outstanding during the period. Options and warrants are
not considered since considering such items would have an antidilutive effect.
<PAGE>
NOTE 4 - GOING CONCERN
The accompanying financial statements have been prepared assuming the
Company will continue as a going concern. The company reported a net loss of
$337,473 and $496,432 for the three and nine months ended August 31, 2000 as
well as reporting net losses of $4,001,010 from inception (December 24, 1997) to
August 31, 2000. As reported on the statement of cash flows, the Company had
negative cash flows from operating activities of $674,164 for nine months ended
August 31, 2000 and has reported deficient cash flows from operating activities
of $2,265,282 from inception (December 24, 1997). To date, these losses and cash
flow deficiencies have been financed principally through the sale of common
stock ($925,764), paid in capital ($1,165,000) and notes payable, principally
related parties (net of discount) ($1,223,853). Additional capital and/or
borrowings will be necessary in order for the Company to continue in existence
until attaining and sustaining profitable operations. Management has continued
to develop a strategic plan to develop a management team, maintain reporting
compliance and establish long term relationships with other major organizations
to develop and distribute the product Malarex. Management anticipates generating
revenue through the sales of Malarax during the next fiscal year. The major
shareholder's of the organization have committed to fund the operations of the
organization during the next fiscal year until the organization can generate
sufficient cash flow from operations to meet current operating expenses and
overhead.
NOTE 5 - ACQUISITION OF SWORD COMP-SOFT
On May 29, 2000, the company acquired thirty five million seven hundred
thousand (35,700,000) shares of Sword Comp-Soft Corp., this being 51% of Sword's
authorized capital, at a cost of five million (5,000,00) common shares, valued
at the average thirty date trading range (OTC other) of $1.50 or seven million
five hundred thousand dollars ($7,500,000) and five million warrants
(5,000,000), entitling the registered holder thereof to purchase at any time
from that date for a period of three (3) years, one share of common stock at a
price of two dollars ($2).
Sword Comp-Soft Corp. is an (ASP) Application Service Provider incorporated in
November 1998 specializing in the E-Healthcare sector.
NOTE 6 - STOCKHOLDER'S EQUITY
One of our founders was invited to participate at the inception of the
Corporation based upon his ability in the area of Investor Relations. However,
shortly thereafter, due to changed personal circumstances, he was unable to
devote significant time and effort to the company. Following ongoing discussions
on January 20, 2000, he agreed to return his 1,000,000 shares to the Corporate
Treasury for cancellation.
On March 20, 1999 the company issued 1,075,000 common shares to Richgold
Corporation SA at the fair market value of $1.36275 per share for marketing
services performed. Due to the fact that the results of these services did not
live up to the company`s expectations, it was agreed upon by the company and
Richgold that Richgold would reimburse $1,165,000 to Millenia. This entire
amount has been applied to paid in capital.
<PAGE>
Item 2. Plan of Operation.
The following discussion should be read in conjunction with the financial
statements and related notes which are included elsewhere in this prospectus.
Statements made below which are not historical facts are forward-looking
statements. Forward-looking statements involve a number of risks and
uncertainties including, but not limited to, general economic conditions and our
ability to market our product.
Some of the statements hereunder are forward-looking statements that
involve risks and uncertainties. These forward-looking statements include
statements about our plans, objectives, expectations, intentions and assumptions
and other statements contained herein that are not statements of historical
fact. You can identify these statements by words such as "may," "will,"
"should," "estimates," "plans," "expects," "believes," "intends" and similar
expressions. We cannot guarantee future results, levels of activity, performance
or achievements. Our actual results and the timing of certain events may differ
significantly from the results discussed in the forward-looking statements. You
are cautioned not to place undue reliance on any forward-looking statements.
The business objectives of Millenia are twofold.
First and foremost is to establish MALAREX as an accepted control agent for the
treatment and prevention of malaria throughout the world. Not only do we believe
that MALAREX is an effective anti-malarial drug, it will also be made available
at prices that are adapted to the realities of the third world market. The
availability and pricing of MALAREX will hopefully ensure its acceptability and
use in the fight against malaria. To this end the company has entered into
clinical trials of MALAREX with the following three countries:
o On October 5th, 1999 India's Directorate of Health accepted MALAREX for
both in-vitro (test-tube) and in-vivo (live trials) testing. On February
28th, 2000 the in-vitro tests were successfully completed and the in-vivo
tests are scheduled to be run next.
o On January 13th, 2000 Cameroun's Department of Health accepted MALAREX for
both in-vitro and in-vivo testing. As of February 17th, 2000 the above
testing was successfully concluded. The company is waiting for the final
approval of the Department of Health for MALAREX to be sold in Cameroun.
While management believes that sales of MALAREX should commence within the
next six months in Cameroun, as there are no signed sales contracts and the
company has not yet received its final certification, there is no basis for
assurance that this will take place.
o On January 26th, 2000 the Ministry of Health and Welfare of Equatorial
Guinea accepted MALAREX for both in-vitro and in-vivo testing. As of
February 27th, 2000 the in-vitro testing was successfully concluded and we
are waiting for the in-vivo testing to be concluded. If this step is
successful then final approval of the ministry of Health and Welfare would
be needed to commence sales of MALAREX.
Millenia has adopted an extremely conservative sales forecast. In the face of
anti-malarial drug resistance, the need for more effective treatments will
continue to intensify. Once a network of local manufacturers and distributors
capable of producing and supplying MALAREX are in place, the demand for MALAREX
should increase commensurately.
It is estimated the demand for MALAREX will increase as it becomes an accepted
choice in the fight against malaria. Millenia chooses to remain conservative in
its sales estimation as it strives to attain its target goal of 2 % of the
marketplace in five years.
Achieving these modest levels will ensure both the viability and profitability
for both the Company and its shareholders.
Secondly, Millenia is committed to ongoing research and development to expand
the efficacy of MALAREX and its derivatives in fighting infectious diseases. To
this end, the company has a verbal agreement with one of its officers, Mr.
Guiseppe Bertelli Motta, VP of research and a co-discoverer of MALAREX whose
profession is botanical research, that it will have the first right of refusal
on all the research carried on by him. As cash flow improves, further funding
will be committed to research and development.
As an integral part of this development, Millenia hopes to establish long term
relationships with other major organizations such as Rotary Against Malaria
(RAM), World Health Organization and the Centres for Disease Controls. It is
through these relationships that Millenia feels that they can best support the
efforts of such organizations to solve the problem of malaria by building an
infrastructure necessary to control this disease.
Currently, Millenia is running a new series of tests, under the auspices of Dr.
Mary Stevenson of McGill University. Dr. Stevenson, an expert on the study of
malaria and a member of the board of the Malaria Foundation International,
expects that, with the successful completion of all the trial phases, the
Canadian government will issue MALAREX a DIN (Drug Identification Number).
Receiving a Canadian DIN is a sign that we have a product that has gone through
a rigorous testing process akin to receiving an ISO 9000 designation.
<PAGE>
As the Company has not yet begun to sell the Product, it is difficult for
management to evaluate the growth curve of Product sales. However, given the
potential market size and the need for viable and effective drugs, the Company
believes that it will not have a problem generating sales thereby creating
positive cash flow once the Product is approved.
On September 26, 2000 Millenia's PCT (International) Patent Application was
accepted and Millenia has now commenced the process of registering its patent
protection in the following 52 countries: the United States, Canada, Europe,
Japan, the states served by the European Patent Office, the African Regional
Industrial Property Organization (ARIPO) and the African Intellectual Property
Organization (OAPI) as well as Brazil, India, Mexico, South Africa, Vietnam and
Madagascar. As well, Millenia has made trademark applications for MALAREX in
these 52 countries.
In the future, as other products are developed and come on line or are
purchased, Millenia will take all necessary steps to see that its product have
the full measure of legal protection. Furthermore; should there be any questions
of infringement on its proprietary rights, Millenia will be aggressive in
asserting its legal position.
The Company intends to use the Internet for advertising as that currently allows
the greatest visibility for very small costs. In fact, the Company believes that
it will be able to obtain free access on certain websites looking for products
such as the Company's.
There is currently insufficient funds to adequately provide for the Company's
needs over the next twelve months, however, the officers and certain
shareholders have committed to fund the operations of the company during the net
twelve months until the company can generate sufficient cash flow from
operations to meet current operating expenses and overhead.
Liquidity and cash flow needs of the company
From December 1st, 1999 to August 31st, 2000 the company and its subsidiary
incurred operating expenses of $568,174 and interest expenses in the amount of
$27,770 while recording net cash revenues of $77,573. From September 1st, 2000
to November 30th, 2000, the fiscal year end, the company anticipates that its
net cash flow needs, including that of its subsidiary, will be $185,000
primarily to cover day to day operating expenses. These funds will be covered by
revenue received and any shortfalls will be met by the officers and certain
shareholders as previously outlined.
On January 20, 2000, after ongoing discussions, one of the founding shareholders
agreed to return his 1,000,000 shares to the company's treasury due to his
inability to provide certain services to the corporation.
On May 29, 2000, the company acquired thirty five million seven hundred thousand
(35,700,000) shares of SWORD COMP-SOFT CORP., this being 51% of SWORD's
authorized capital, at a cost of five million (5,000,000) common shares, valued
at the average thirty date trading range (OTC other) of $1.50 or seven million
five hundred thousand dollars ($7,500,000) and five million warrants
(5,000,000), entitling the registered holder thereof to purchase at any time
from that date for a period of three (3) years, one share of common stock at a
price of two dollars ($2).
SWORD COMP-SOFT CORP. is an (ASP) Application Service Provider incorporated in
November 1998 specializing in the E-Healthcare sector.
<PAGE>
Application services, a rapidly growing segment of the Internet economy, are
those that focus on a single topic or issue in a conversational manner.
Sword has what it believes is some of the most advanced technology currently
available in the field of e-Healthcare and that it will be in a position to
offer a range of application services designed around the concept of providing a
series of useful, on line interactive health services and facilities in an
attractive, convenient format to people in their electronic environments. These
application services include the identification and personal logging of
disease(s) and strategies to cope with long term health issues from nutrition,
wellness and health in a "patient driven" format.
Essentially, the subscribers use application programs to create, store and
transact medical data on the application server, for example, the interactive
on-line health service will record similar data to that usually given to a
primary health care worker, such as a doctor or a nurse,, and create an overall
profile of individual health needs. Each application will relate to a specific
disease, drug, or part of the human anatomy on a pay per use basis ( although
this fee may be sponsored).
On March 20, 1999 the company issued 1,075,000 common shares to Richgold
Corporation SA at the fair market value of $1.36275 per share for marketing
services performed. Due to the fact that the results of these services did not
live up to the company`s expectations, it was agreed upon by the company and
Richgold that Richgold would reimburse $1,165,000 to Millenia. This entire
amount has been applied to paid in capital.
On February 22, 2000 Dr. David Mulder joined the Board of Directors of Millenia
Hope as its Vice-Chairman of the Board. Dr Mulder, a world-renowned physician in
several disciplines, was the former chairman of Montreal's McGill University
department of surgery and the surgeon-in-chief at the Montreal General Hospital
for 21 years. Dr Mulder has held leading positions in several important medical
associations.
At a Board of Directors meeting, held on April 19, 2000, Dr. Alain Soucy,
Chairman of the Board of Millenia, resigned in order to head up a new start-up,
Thermolysis International, a corporation specializing in industrial water (and
waste) purification.
At the same meeting, Dr. George Haligua, Vice President of Finance and a
Director, has resigned to devote more time and concentrate his efforts on his
own principle businesses.
Dr. George Tsoukas is the newly elected chairman of the Board of Millenia Hope.
Dr. George Tsoukas has a bachelor of science in Biochemistry from McGill
University and received his Medical degree from McGill in 1968. In 1975 he was
granted a specialization in Internal Medicine and Endocrinology from the same
institution. For over 10 years, he has been an Associate Physician at the McGill
University Medical Center and is currently conducting clinical research on bone
diseases. Dr. Tsoukas was also the chief examiner for the Quebec College of
Endocrinologists from 1980 - 1986. Dr. Tsoukas is a well known educator who,
over the past decade, has produced medical CD-ROMs and hosted a popular TV
program explaining medical conditions. He has also lectured extensively to other
doctors on behalf of major pharmaceutical companies.
Mr. Leonard Stella, President and Treasurer, will take over the financial
responsibilities of Dr. Haligua and will share, with Mr. Tom Bourne, Secretary
of Millenia, the duties involved in shareholder relations previously handled by
Dr. Haligua. Mr. Stella's title will now be COO, Chief Operating Officer,
replacing his previous designation as President and Treasurer.
<PAGE>
As of August 31, 2000 Millenia had entered into the final stages of negotiation
to acquire an interest in Cibecol Industrial Farmaceutica. Millenia has a
$500,000 US deposit pending the final outcome of these negotiations. Cibecol
operates a 20,000 square foot manufacturing facility and also owns 80 hectars of
arable land, located, in Porto Allegre, Brazil. Millenia will use the Brazilian
facility for the production of Malarex.
Cibecol operates one of the largest phyto-pharmaceutical plants in southern
Brazil. In addition to producing voacamine, the active agent in Malarex, Cibecol
would continue to produce its own group of 61 natural medicines that are
currently being Marketed in Brazil.
This acquisition would be a key step forward toward Millenia's goal of becoming
A vertically integrated producer and distributor of Malarex.
Furthermore, Millenia is in the process of finalizing a scientifically
beneficial and potentially lucrative project, under the leadership of Dr. David
Mulder, Millenia's Vice-Chairman, and Dr. Rene Morel, a member of our scientific
committee, which we call 02-IV-oxygenation of intravenous solutions.
In 02-IV we will be introducing a new concept in that intravenous solution
recipients will now be able to derive a positive boost from the extra dose of
oxygen delivered directly to their blood stream.
As per the January 1999 article in the Canadian Journal of Health & Nutrition
titled, "Oxygen Boosts Performance", the benefits of additional oxygen for the
body are numerous. Cardiovascular endurance, especially if the patient has heart
or pulmonary problems, heads this list. Added supplies of oxygen raises the
human body's energy levels, gives greater muscular endurance, improves
concentration, calms the nervous system and helps in the removal of toxins.
These benefits are of extreme importance to ambulatory patients, as their body
is not getting the exercise that is so necessary to proper oxygen consumption.
The North American intravenous solution market, per estimates of Frost &
Sullivan, is approximately $1.3 billion and the rest of the international market
is about an additional $1.5 billion.
Millenia hopes to conclude the deal to license the technology, that allows for
the oxygenation of intravenous solutions currently held by Liquid Asset
Corporation of Delaware, by its year end. Millenia has a $500,000 US deposit
pending the finalization of the aforementioned.
<PAGE>
Part II other information
Item 2: Sales of Unregistered securities
Date of Title of Number Consideration Exemption from
Sale Security Sold Received Registration claimed
1/17/2000 Common 563,000 $ 50,670 Regulation S
Shares
2/28/2000 Warrants 4,644,156 cancellation of
exercisable of notes payable
at $1.00 per and long term
share until debt Regulation S
11/30/2002 $ 1,393,247
29/5/2000 common shares 5,000,000 35,700,000 Section 4(2)
shares of
Sword Comp-
Soft Corp.
31/5/2000 common shares 4.401.019 396.092 Regulation S
10/7/2000 common shares 353,351 31.802 Regulation S
ITEM 6: EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
27. Financial Data Schedule (8/31/00)
(b) Reports on Form 8-K
None
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Millenia Hope Inc.
(Registrant)
Dated: October 23, 2000 By: /s/ Leonard Stella
President and Treasurer